NCT06906978Not yet recruiting
Single Cell Acute Leukemia Analysis
Source: ClinicalTrials.gov · Last updated 10 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Numerous chemotherapy and immunotherapy resistance genes have been identified in cancers in general and acute myeloid leukemia in particular. As a preliminary to this study, the investigators hypothesized the co-expression of these genes in the same cell as a major factor in relapse. This hypothesis was supported in vitro by the study of the evolution of these co-expressions after incubation with chemotherapy drugs. The current study aims to verify this hypothesis by studying the expression of these genes in single-cell samples from relapsed acute myeloid leukemia patients.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 26 Mar 2025
- Start date
- 31 Jul 2025
- Primary completion date
- 31 Jul 2028
- Lead sponsor
- Assistance Publique Hopitaux De Marseille
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT06906978
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 31 Jul 2025 to the primary completion date, 31 Jul 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Persons who do not understand the French language if there is no translator available to translate for them.
- Absence of circulating blastosis.
Who the study is looking for
- Adult patient
- Patient who has received information about the study and has not expressed opposition,
- Patients who are beneficiaries of a social security plan,
- Patient with relapsed or refractory acute myeloid leukemia, whatever the previous treatment, the therapeutic line and the time between the previous treatment and the relapse.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.